Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics completes recruitment for phase III birch pollen trial

Results from study of PQ Birch are expected in the second half of this year
woman sneezing
Work will get underway during the birch pollen season

Allergy Therapeutics plc (LON:AGY) has completed the recruitment to a European phase III clinical trial of its ultra-short course treatment for people allergic to birch pollen.

Results from study of PQ Birch are expected in the second half of this year. Researchers will assess the efficacy of the aluminium-free inoculation alongside the safety of the injection.

READ: Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic

A total of 560 people from 59 different centres in Germany, Austria, Poland and Sweden are taking part in the trial, which will get underway during birch pollen season.

Success would pave the way for marketing authorisation. Chief executive Manuel Llobet said the successful development of PQ Birch would “strengthen the group's portfolio and help address the current unmet needs”.

READ: Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic

The product is one of a number of ultra-short course, injected immunotherapy products in clinical development for various allergies, which are part of Allergy Therapeutics’ three-pillar strategy. The company is investing heavily from its growing revenue stream in its pipeline as well as expanding its base in Europe, while preparing for entry to the US.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
bacteria
09:00
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use